Notice of AriBioLab Website Renewal

We start English website service. Thank you for waiting this.

+ Learn more
close
AriBioLab (주) 차백신연구소
  • About us
    • What we do
    • Mission & Strategy
  • R&D
    • Pipeline
    • HBV vaccine projects
    • 3rd gen. HBV vaccine
    • HBV therapeutic vaccine
    • Zoster vaccine
    • Flu vaccine
    • Adjuvant
    • Recombinant MBL
  • Our News
    • News & Events
KOR
  • AriBioLab
    Immune Innovation Company

    Research-oriented biotechnology company focused on
    the prevention and treatment of Infectious diseases

  • AriBioLab
    Immune Innovation Company

    Research-oriented biotechnology company focused on
    the prevention and treatment of Infectious diseases

  • AriBioLab
    Immune Innovation Company

    Research-oriented biotechnology company focused on
    the prevention and treatment of Infectious diseases

  • 3rd gen. HBV vaccine

    Improved HBV vaccine using the
    3rd generation antigen L-HBsAg
    containing preS and S proteins

  • HBV therapeutic vaccine

    Therapeutic vaccine for the
    chronic hepatitis B patients and
    carriers

  • Zoster vaccine

    Recombinant vaccine to reduce
    the incidence of herpes zoster
    and to alleviate the postherpetic
    neuralgia.

  • Flu vaccine

    Improved influenza vaccine using
    novel adjuvant L-pampo

  • Adjuvant

    Immune stimulating material to
    enhance the efficacy of a vaccine,
    based on the TLR ligands

  • Recombinant MBL

    Immunotherapeutic protein to
    suppress the infection of the
    broad range of pathogenic
    micro-organisms as the first line
    of defense

top
    SITEMAP
560 Dunchon-daero, Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea 13230 Tel. 82-31-737-8208 Fax. 82-31-737-8210
COPYRIGHT © 2026 AriBioLab. ALL RIGHT RESERVED
Family site
  • aribio.com
  • herzion.com
  • bidanfiller.com
  • mytox.co.kr
Comprehensive
Anti-aging Life
Centers
  • Chaum